In addition, targeting MYBL2 blocks bone metastasis in prostate cancer cells, and higher MYBL2 expression levels are associated with higher tumor stage, higher tumor grade, higher risk of metastatic relapse, and worse prognosis in patients with prostate cancer [34]. The gene discussed is MYBL2; the disease is prostate carcinoma.